Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science: synthesis, in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of new targeted radiotracers. The importance of the target to an unmet clinical need should be the first consideration. If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized.
These multidisciplinary studies should validate the mechanism of localization whether the probe is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the probe to changes in disease or treatment, although studies validating mechanism alone are acceptable. Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field.
Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed.
《NUCLEAR MEDICINE AND BIOLOGY》期刊已被查看: 次
此期刊被最新的JCR期刊SCIE收录
期刊官网:http://www.journals.elsevier.com/nuclear-medicine-and-biology/ |
---|
期刊投稿网址:https://www.editorialmanager.com/NUCMEDBIO |
PubMed Central (PMC)链接 :http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0969-8051%5BISSN%5D |
通讯地:ELSEVIER SCIENCE INC, 360 PARK AVE SOUTH, NEW YORK, USA, NY, 10010-1710 |
中国科学院《国际期刊预警名单(试行)》名单 |
2024年02月发布的2024版:不在预警名单中 2023年01月发布的2023版:不在预警名单中 2021年12月发布的2021版:不在预警名单中 2020年12月发布的2020版:不在预警名单中 此期刊被最新的JCR期刊SCIE收录 |
版面费 | 审稿速度 | 收录数据库 | 是否oa | 研究方向 |
---|---|---|---|---|
一般,3-8周<br>来源Elsevier官网:平均8周 | SCIE,Scopus | No | 医学-核医学 |
大类学科 | 分区 | 小类学科 | Top期刊 | 综述期刊 |
---|---|---|---|---|
医学 | 4区 | RADIOLOGY NUCLEAR MEDICINE & MEDICAL IMAGING 核医学 |
否 | 否 |
版本 | 按学科 | 分区 | 影响因子 |
---|---|---|---|
2023-2024年最新版 | RADIOLOGY NUCLEAR MEDICINE & MEDICAL IMAGING |
Q1 | 3.6 |
Journal of Inclusive Postsecondary EducationJCR:0区,分类:影响因子0收录DOAJ
详情StichprobenJCR:0区,分类:影响因子0收录DOAJ
详情EManagementJCR:0区,分类:影响因子0收录DOAJ
详情Metathesis Journal of English Language Literature and TeachingJCR:0区,分类:影响因子0收录DOAJ
详情Clinical Psychology in EuropeJCR:0区,分类:影响因子0收录Scopus,DOAJ
详情Ius InkarriJCR:0区,分类:影响因子0收录DOAJ
详情Medichna nauka UkrayiniJCR:0区,分类:影响因子0收录DOAJ
详情Economics LawJCR:0区,分类:影响因子0收录DOAJ
详情